ScinoPharm Taiwan, Ltd. (TWSE: 1789) and Raffles PharmaTech announced today the collaboration to manufacture “ Celecoxib”, a non-steroidal and anti-inflammatory analgesic active pharmaceutical ingredient (API) .

ScinoPharm Taiwan, Ltd (TWSE: 1789), an active pharmaceutical ingredient (API) and formulation specialty company, today announced unaudited financial results for its fiscal year 2014.

ScinoPharm Taiwan, Ltd (TWSE: 1789) and Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. (hereinafter refer to as NKF) announced today the joint research and development of a new drug, Regadenoson.

ScinoPharm (TWSE:1789) announced that after 17 years of dedicated service, its co-founder and President & CEO Dr. Jo Shen is retiring at the end of July, 2014 and will be succeeded by Dr. Yung-Fa (Fred) Chen, currently Sr. Vice President of R&D and Chief Technology Officer, effective August 1, 2014.

ScinoPharm, a leading global supplier of active pharmaceutical ingredients (APIs), today announced the appointment of Kevin Yen as Vice President of Administration. He will report directly to Dr. Jo Shen, President and CEO of ScinoPharm.